Quinazolinone antibiotics
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 25, 2019
Grant Date -
Feb 1, 2018
app pub date -
Oct 2, 2017
filing date -
Mar 5, 2013
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A new class of antibiotics effective against methicillin-resistant Staphylococcus aureus (MRSA) is disclosed (Formula V). Compounds of this class can impair cell-wall biosynthesis by binding to both the allosteric and the catalytic domains of penicillin-binding protein (PBP) 2a. This class of antibiotics holds promise in reversing obsolescence of staphylococcal PBPs as important targets for antibiotics. Embodiments of the invention thus provide novel antibacterial compounds that target penicillin-binding proteins and/or other important cellular targets. Methods for inhibiting the growth and/or replication of bacteria using the compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, including drug-resistant strains of Staphylococcus aureus.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully